Cargando…
Future Risks in Patients With Severe Asthma
A major burden of severe asthma is the future risk of adverse health outcomes. Patients with severe asthma are prone to serious exacerbation and deterioration of lung function and may experience side effects of medications such as oral corticosteroids (OCSs). However, such future risk is not easily...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761069/ https://www.ncbi.nlm.nih.gov/pubmed/31552713 http://dx.doi.org/10.4168/aair.2019.11.6.763 |
_version_ | 1783453944795627520 |
---|---|
author | Song, Woo-Jung Lee, Ji-Hyang Kang, Yewon Joung, Woo Joung Chung, Kian Fan |
author_facet | Song, Woo-Jung Lee, Ji-Hyang Kang, Yewon Joung, Woo Joung Chung, Kian Fan |
author_sort | Song, Woo-Jung |
collection | PubMed |
description | A major burden of severe asthma is the future risk of adverse health outcomes. Patients with severe asthma are prone to serious exacerbation and deterioration of lung function and may experience side effects of medications such as oral corticosteroids (OCSs). However, such future risk is not easily measurable in daily clinical practice. In particular, currently available tools to measure asthma control and asthma-related quality of life incompletely predict the future risk of medication-related morbidity. This is a significant issue in asthma management. This review summarizes the current evidence of future risk in patients with severe asthma. As future risk is poorly perceived by controlled asthmatics, our review focuses on the risk in patients with ‘controlled’ severe asthma. Of note, it is likely that long-term OCS therapy may not prevent future asthma progression, including lung function decline. In addition, the risk of drug side effects increases even during low-dose OCS therapy. Thus, novel treatments are highly desirable for reducing future risks without any loss of asthma control. |
format | Online Article Text |
id | pubmed-6761069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-67610692019-11-01 Future Risks in Patients With Severe Asthma Song, Woo-Jung Lee, Ji-Hyang Kang, Yewon Joung, Woo Joung Chung, Kian Fan Allergy Asthma Immunol Res Review A major burden of severe asthma is the future risk of adverse health outcomes. Patients with severe asthma are prone to serious exacerbation and deterioration of lung function and may experience side effects of medications such as oral corticosteroids (OCSs). However, such future risk is not easily measurable in daily clinical practice. In particular, currently available tools to measure asthma control and asthma-related quality of life incompletely predict the future risk of medication-related morbidity. This is a significant issue in asthma management. This review summarizes the current evidence of future risk in patients with severe asthma. As future risk is poorly perceived by controlled asthmatics, our review focuses on the risk in patients with ‘controlled’ severe asthma. Of note, it is likely that long-term OCS therapy may not prevent future asthma progression, including lung function decline. In addition, the risk of drug side effects increases even during low-dose OCS therapy. Thus, novel treatments are highly desirable for reducing future risks without any loss of asthma control. The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2019-07-08 /pmc/articles/PMC6761069/ /pubmed/31552713 http://dx.doi.org/10.4168/aair.2019.11.6.763 Text en Copyright © 2019 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Song, Woo-Jung Lee, Ji-Hyang Kang, Yewon Joung, Woo Joung Chung, Kian Fan Future Risks in Patients With Severe Asthma |
title | Future Risks in Patients With Severe Asthma |
title_full | Future Risks in Patients With Severe Asthma |
title_fullStr | Future Risks in Patients With Severe Asthma |
title_full_unstemmed | Future Risks in Patients With Severe Asthma |
title_short | Future Risks in Patients With Severe Asthma |
title_sort | future risks in patients with severe asthma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761069/ https://www.ncbi.nlm.nih.gov/pubmed/31552713 http://dx.doi.org/10.4168/aair.2019.11.6.763 |
work_keys_str_mv | AT songwoojung futurerisksinpatientswithsevereasthma AT leejihyang futurerisksinpatientswithsevereasthma AT kangyewon futurerisksinpatientswithsevereasthma AT joungwoojoung futurerisksinpatientswithsevereasthma AT chungkianfan futurerisksinpatientswithsevereasthma |